Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates

Cayla A. Wood, Sangheon Han, Chang Soo Kim, Yunfei Wen, Diego R. T. Sampaio, Justin T. Harris, Kimberly A. Homan, Jody L. Swain, Stanislav Y. Emelianov, Anil K. Sood, Jason R. Cook, Konstantin V. Sokolov () and Richard R. Bouchard ()
Additional contact information
Cayla A. Wood: The University of Texas MD Anderson Cancer Center
Sangheon Han: The University of Texas MD Anderson Cancer Center
Chang Soo Kim: The University of Texas MD Anderson Cancer Center
Yunfei Wen: The University of Texas MD Anderson Cancer Center
Diego R. T. Sampaio: The University of Texas MD Anderson Cancer Center
Justin T. Harris: NanoHybrids, Inc.
Kimberly A. Homan: NanoHybrids, Inc.
Jody L. Swain: The University of Texas MD Anderson Cancer Center
Stanislav Y. Emelianov: School of Electrical and Computer Engineering, Georgia Institute of Technology
Anil K. Sood: The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Jason R. Cook: NanoHybrids, Inc.
Konstantin V. Sokolov: The University of Texas MD Anderson Cancer Center
Richard R. Bouchard: The University of Texas MD Anderson Cancer Center

Nature Communications, 2021, vol. 12, issue 1, 1-13

Abstract: Abstract Photoacoustic (PA) imaging is a functional and molecular imaging technique capable of high sensitivity and spatiotemporal resolution at depth. Widespread use of PA imaging, however, is limited by currently available contrast agents, which either lack PA-signal-generation ability for deep imaging or their absorbance spectra overlap with hemoglobin, reducing sensitivity. Here we report on a PA contrast agent based on targeted liposomes loaded with J-aggregated indocyanine green (ICG) dye (i.e., PAtrace) that we synthesized, bioconjugated, and characterized to addresses these limitations. We then validated PAtrace in phantom, in vitro, and in vivo PA imaging environments for both spectral unmixing accuracy and targeting efficacy in a folate receptor alpha-positive ovarian cancer model. These study results show that PAtrace concurrently provides significantly improved contrast-agent quantification/sensitivity and SO2 estimation accuracy compared to monomeric ICG. PAtrace’s performance attributes and composition of FDA-approved components make it a promising agent for future clinical molecular PA imaging.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25452-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25452-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25452-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().